Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

855.50INR
10:23am GMT
Change (% chg)

Rs-9.20 (-1.06%)
Prev Close
Rs864.70
Open
Rs868.00
Day's High
Rs875.00
Day's Low
Rs851.70
Volume
1,287,405
Avg. Vol
3,024,563
52-wk High
Rs986.10
52-wk Low
Rs723.65

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  LUPN.NS Industry Sector
P/E (TTM): 23.14 31.23 33.59
EPS (TTM): 44.89 -- --
ROI: -- 15.57 15.05
ROE: -- 16.94 16.62

UPDATE 1-India's Lupin Q2 profit dives as U.S. sales, higher expenses weigh

Oct 31 Lupin Ltd, India's second-largest drugmaker by revenue, posted a lower-than-expected second-quarter profit on Wednesday, as sales in the United States - a key market - dropped and overall manufacturing costs rose.

31 Oct 2018

India's Lupin Q2 profit falls, misses estimates

Oct 31 Lupin Ltd, India's second-largest drugmaker by revenue, posted a 41.5 percent fall in second-quarter profit on Wednesday, hurt by higher expenses.

31 Oct 2018

UPDATE 1-India's Lupin Q1 profit misses estimate by wide margin

Aug 8 Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan.

08 Aug 2018

India's Lupin quarterly profit falls 43 pct

Aug 8 Drugmaker Lupin Ltd posted a 43 percent fall in first-quarter profit on Wednesday, widely missing analysts' estimates.

08 Aug 2018

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

24 May 2018

Earnings vs. Estimates